The flow-chart describing participant inclusion is shown in Fig. 1. Description of the study population A total of 131 patients (55 in the RCA group and 76 in the systemic heparin group) were included in the analysis. The demographic and clinical characteristics of the patients were largely ...
Patients assigned to receive subcutaneous low-molecular-weight heparin also received an intravenous placebo bolus and a continuous intravenous infusion of placebo throughout initial therapy. To maintain double-blinding, APTTs were reported only to a member of the health care team not involved in ...
The objective of this study was to assess a weight-based heparin (WBH) nomogram (80-U/kg bolus, 18-U/kg-per-hour initial infusion) and determine its clinical performance and impact on resource utilization. All patients treated with heparin for venous thromboembolism or unstable angina during ...
A pilot RCT with VV-ECMO patients showed no differences in oxygenator changes, transfusions and bleeding complications between standard-dose UFH and a non-titrating weight-based UFH infusion [43]. Other clinical trials (RATE-trial, NCT04536272; CASUAL-ECMO trial NCT06442267) are still ongoing ...